NL-OMON20125招募中不适用
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor
VU University medical centerProf. E. Boven, MD, PhD, medical oncologistDe Boelelaan 11171081 HV AmsterdamPhone: 020-444 4336E-mail: e.boven@vumc.nltogether with:Borstkanker Onderzoek Groep(BOOG) Dr. A.E. van Leeuwen-Stok, research-managerP.O. Box 9236, 1006 AE AmsterdamPhone: 020-346 2547Fax: 020-346 2525E-mail: boog@ikca.nl0 个研究点目标入组 312 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 312
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with histologically or cytologically confirmed, HER2/neu-negative, pre- or postmenopausal adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy. Locally recurrent disease must not be amenable to resection and/or radiotherapy with curative intent.
- •2. Documented ER/PR status
排除标准
- •* Previous treatment
- •Previous chemotherapy for locally recurrent or metastatic breast cancer
研究者
相似试验
进行中（未招募）
不适用
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) - ATXEUCTR2006-006058-83-NLVU Medisch Centrum
已完成
2 期
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT03662542Janssen Research & Development, LLC214
已完成
2 期
Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with metastatic gastric cancerElderly patients with metastatic gastric cancerJPRN-UMIN000009349ational Cancer Center Hospital40
招募中
2 期
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and CarboplatinLung Cancer, Small CellNCT06698965Shanghai Chest Hospital52
已完成
2 期
Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)Colorectal cancerJPRN-UMIN000012063Kurume University Medical Center30